The promise and challenges of combination therapies with antibody-drug conjugates in solid tumorsQing Wei, Xiangdong Cheng, Lu Sun et al.|Journal of Hematology & Oncology|2024Cited by 157
A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.Chunmei Bai, Jin Li, Junli Xue et al.|Journal of Clinical Oncology|2024Cited by 16